中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 10
Oct.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(10): 2224-2229

Dynamic changes of serum hepatitis B virus DNA and HBsAg in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate for 3 years

DOI: 10.3969/j.issn.1001-5256.2022.10.006

  • Department of Infectious Disease, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China

Research funding:

Key R & D Program of Shannxi (General Project) (2020SF-297)

More Information
  • Corresponding author: LI Mei, l.m.2010@163.com(ORCID: 0000-0001-6295-4270)
  • Received Date: 2022-03-26
  • Accepted Date: 2022-05-27
  • Published Date: 2022-10-20
    Abstract
  •   Objective  To assess the efficacy of tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB) patients receiving antiviral therapy for three years.  Methods  A total of 157 CHB patients treated with TDF alone for ≥3 years from January 2015 to August 2020 in the Second Affiliated Hospital of Xi'an Jiaotong University were retrospectively studied. The patients were divided into HBeAg-positive and HBeAg-negative groups based on their baseline HBeAg levels. The data of serum HBV DNA and HBsAg levels at baseline, the first, second and third year of treatment were collected to analyze the dynamic changes. The t-test was used to compare continuous variables with normal distributions between two groups, while the Mann-Whitney U test was used to compare continuous variables with non-normal distribution between two groups. Repeated measurement data with non-normal distribution were first transformed into logarithms and the intra- or between-group comparison was performed using repeated measures analysis of variance. The chi-square test or Fisher exact test was used to compare categorical variables between groups.  Results  HBV DNA clearance rate in HBeAg-positive patients was significantly lower than that in HBeAg-negative patients during the first and second years of TDF treatment (1st year: 65.8% vs 81.0%, χ2=4.676, P < 0.05; 2nd year: 87.7% vs 98.8%, Fisher exact test, P < 0.05). When TDF treatment was given for three years, there was no significant difference in HBV DNA clearance rates (97.3% vs 100%, Fisher exact test, P > 0.05). The baseline HBsAg levels in HBeAg-positive and HBeAg-negative patients were 10 633.6 (2 084.8-24 005.7) IU/mL and 1 402.8 (311.0-2 863.5) IU/mL, respectively, and decreased to 1 534.9 (912.7-5 885.9) IU/mL and 677.8 (119.4-1 974.8) IU/mL after 3 years of TDF treatment, with a significant difference between two groups (F=25.456, P < 0.001). In HBeAg-positive patients, the median decline value of HBsAg level was significantly higher in the first year [1 856.5 (158.4-12 103.1) IU/mL] than in the second year [879.8 (130.5-2 382.5) IU/mL] or the third year [479.9 (95.0-1 662.4) IU/mL] (F=10.972, P < 0.001), while there was no significant difference in HBeAg-negative patients (F=0.513, P > 0.05). In addition, after 3 years of TDF treatment, 59.2% of patients achieved HBsAg < 1500 IU/mL, with a HBsAg negative rate of 1.3%.  Conclusion  After 3 years of TDF treatment, all HBeAg-negative CHB patients can achieve HBV DNA negative conversion; for HBeAg-positive CHB patients, 97.3% of them achieved HBV DNA negative conversion, while 2.7% of them were still HBV DNA detectable. The HBsAg level declined over treatment time, and the decline rate of HBsAg level in HBeAg positive patients showed a trend of "first fast and then slow". After 3 years of TDF treatment, 59.2% of patients achieved HBsAg < 1500 IU/mL.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
    [3]
    NA JH, KIM JH, CHOE WH, et al. Changes in the hepatitis B surface antigen level according to the HBeAg status and drug used in long-term nucleos(t)ide analog-treated chronic hepatitis B patients[J]. Korean J Gastroenterol, 2021, 77(6): 285-293. DOI: 10.4166/kjg.2021.043.
    [4]
    WU FP, LI MX, WANG YK, et al. Dynamic changes of HBsAg and hepatitis B virus DNA in chronic hepatitis B patients after entecavir monotherapy for 5 years[J]. J Clin Hepatol, 2021, 37(5): 1047-1052. DOI: 10.3969/j.issn.1001-5256.2021.05.015.

    吴凤萍, 李妙羡, 王怡恺, 等. 恩替卡韦单药治疗慢性乙型肝炎患者5年HBsAg与HBV DNA的动态变化[J]. 临床肝胆病杂志, 2021, 37(5): 1047-1052. DOI: 10.3969/j.issn.1001-5256.2021.05.015.
    [5]
    RIVEIRO-BARCIELA M, TABERNERO D, CALLEJA JL, et al. Effectiveness and safety of entecavir or tenofovir in a spanish cohort of chronic hepatitis B patients: Validation of the Page-B Score to predict hepatocellular carcinoma[J]. Dig Dis Sci, 2017, 62(3): 784-793. DOI: 10.1007/s10620-017-4448-7.
    [6]
    ZHANG Q, CAI DC, HU P, et al. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients[J]. Chin Med J (Engl), 2021, 134(23): 2810-2817. DOI: 10.1097/CM9.0000000000001793.
    [7]
    LU FM, FENG B, ZHENG SJ, et al. Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues[J]. J Clin Hepatol, 2021, 37(6): 1268-1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007.

    鲁凤民, 封波, 郑素军, 等. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状[J]. 临床肝胆病杂志, 2021, 37(6): 1268-1274. DOI: 10.3969/j.issn.1001-5256.2021.06.007.
    [8]
    TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
    [9]
    BOYD A, LACOMBE K, LAVOCAT F, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients[J]. J Hepatol, 2016, 65(4): 683-691. DOI: 10.1016/j.jhep.2016.05.014.
    [10]
    PARK ES, LEE AR, KIM DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(6): 1093-1102. DOI: 10.1016/j.jhep.2019.02.006.
    [11]
    MOKAYA J, MCNAUGHTON AL, BESTER PA, et al. Hepatitis B virus resistance to tenofovir: fact or fiction? A systematic literature review and structural analysis of drug resistance mechanisms[J]. Wellcome Open Res, 2020, 5: 151. DOI: 10.12688/wellcomeopenres.15992.1.
    [12]
    DI BISCEGLIE AM, KING WC, LISKER-MELMAN M, et al. Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B[J]. J Viral Hepat, 2019, 26(7): 856-865. DOI: 10.1111/jvh.13104.
    [13]
    CHAN HL, WONG VW, WONG GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B[J]. Hepatology, 2010, 52(4): 1232-1241. DOI: 10.1002/hep.23803.
    [14]
    CELIK M, ARABUL M, CEKIÇ C, et al. Clinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infection[J]. Prz Gastroenterol, 2014, 9(3): 164-167. DOI: 10.5114/pg.2014.43758.
    [15]
    ZOUTENDIJK R, HANSEN BE, VAN VUUREN AJ, et al. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss[J]. J Infect Dis, 2011, 204(3): 415-418. DOI: 10.1093/infdis/jir282.
    [16]
    YU Y, HOU J, OMATA M, et al. Loss of HBsAg and antiviral treatment: from basics to clinical significance[J]. Hepatol Int, 2014, 8(1): 39-54. DOI: 10.1007/s12072-013-9495-3.
    [17]
    SETO WK, LIU K, WONG DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment[J]. J Hepatol, 2013, 59(4): 709-716. DOI: 10.1016/j.jhep.2013.06.007.
    [18]
    MANESIS EK, PAPATHEODORIDIS GV, TINIAKOS DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B[J]. J Hepatol, 2011, 55(1): 61-68. DOI: 10.1016/j.jhep.2010.10.027.
    [19]
    LEVRERO M, POLLICINO T, PETERSEN J, et al. Control of cccDNA function in hepatitis B virus infection[J]. J Hepatol, 2009, 51(3): 581-592. DOI: 10.1016/j.jhep.2009.05.022.
    [20]
    Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
    [21]
    HUANG J, ZHANG K, CHEN W, et al. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs[J]. Sci Rep, 2017, 7(1): 13383. DOI: 10.1038/s41598-017-13747-9.
    [22]
    WU FP, YANG Y, LI M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study[J]. World J Gastroenterol, 2020, 26(13): 1525-1539. DOI: 10.3748/wjg.v26.i13.1525.
    [23]
    LI H, XU WT, DENG BC, et al. Research progress of nucleoside analogues combined with peginterferon in functional cure of chronic hepatitis B[J]. Chin J Med Offic, 2022, 50(9): 890-893. DOI: 10.16680/j.1671-3826.2022.09.04.

    李卉, 许文涛, 邓宝成, 等. 核苷(酸)类似物联合聚乙二醇干扰素功能性治愈慢性乙型肝炎研究进展[J]. 临床军医杂志, 2022, 50(9): 890-893. DOI: 10.16680/j.1671-3826.2022.09.04.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (800) PDF downloads(157) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return